title: Intravesical liposome drug delivery and IC/BPS.
abstract: Intravesical therapy has previously shown to be effective in delaying or preventing recurrence of superficial bladder cancer. This local route of drug administration is now demonstrating promise in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) with the benefit of minimal systemic side effects. Liposomes (LPs) are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core. They can incorporate drug molecules, both hydrophobic and hydrophilic, and vastly improve cellular uptake of these drug molecules via endocytosis. Intravesical LPs have therapeutic effects on IC/BPS patients, mainly due to their ability to form a protective lipid film on the urothelial surface and repair the damaged urothelium. This review considers the current status of intravesical LPs and LP mediated drug delivery for the treatment of IC/BPS.
authors.affiliation: Lipella Pharmaceuticals, Inc. Pittsburgh, PA 15208, USA.
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Janicki
authors.affiliation: Lipella Pharmaceuticals, Inc. Pittsburgh, PA 15208, USA.
authors.forename: Michele A
authors.initials: MA
authors.lastname: Gruber
authors.affiliation: Lipella Pharmaceuticals, Inc. Pittsburgh, PA 15208, USA.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Chancellor
keywords: Liposome (LP); bladder; interstitial cystitis (IC)
references.citation: J Cell Sci. 2003 Oct 15;116(Pt 20):4087-94
references.pmid: 12972502
references.citation: Rev Urol. 2010 Fall;12(4):e181-9
references.pmid: 21234261
references.citation: J Urol. 2015 Aug;194(2):578-84
references.pmid: 25839382
references.citation: Rev Urol. 2014;16(2):83-7
references.pmid: 25009448
references.citation: Neurourol Urodyn. 2011 Mar;30(3):421-7
references.pmid: 20860016
references.citation: Urology. 2003 Mar;61(3):656-63
references.pmid: 12639679
references.citation: J Urol. 2009 Aug;182(2):786-92
references.pmid: 19539320
references.citation: Int Urol Nephrol. 2014 Dec;46(12):2291-5
references.pmid: 25209396
references.citation: Trends Biotechnol. 1995 Dec;13(12):527-37
references.pmid: 8595139
references.citation: Science. 2006 Apr 28;312(5773):592-6
references.pmid: 16543415
references.citation: Urology. 2005 Jul;66(1):208-12
references.pmid: 15992889
references.citation: J Urol. 2009 Oct;182(4):1393-400
references.pmid: 19683290
references.citation: J Urol. 2005 Apr;173(4):1182-5
references.pmid: 15758737
references.citation: ISRN Pharmacol. 2014 Jan 15;2014:601653
references.pmid: 24527221
references.citation: Am J Physiol. 1994 Oct;267(4 Pt 1):C1013-26
references.pmid: 7943264
references.citation: Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74
references.pmid: 10836974
references.citation: Int J Nanomedicine. 2012;7:49-60
references.pmid: 22275822
references.citation: Transplant Proc. 2001 May;33(3):2292-3
references.pmid: 11377532
references.citation: BJU Int. 2010 Apr;105(8):1046-58
references.pmid: 22299133
references.citation: Urology. 2013 Dec;82(6):1451.e7-11
references.pmid: 24295264
references.citation: Eur Urol. 2014 Jun;65(6):1117-24
references.pmid: 24555904
references.citation: J Urol. 2011 Aug;186(2):540-4
references.pmid: 21683389
references.citation: J Urol. 2014 Dec;192(6):1743-9
references.pmid: 25046622
references.citation: J Urol. 2004 Oct;172(4 Pt 1):1529-32
references.pmid: 15371885
references.citation: J Urol. 2013 Apr;189(4):1553-8
references.pmid: 23127767
references.citation: Mol Clin Oncol. 2014 Sep;2(5):656-660
references.pmid: 25054027
references.citation: BJU Int. 2009 Dec;104(11):1689-92
references.pmid: 19594739
references.citation: J Urol. 2011 Jun;185(6):2162-70
references.pmid: 21497847
references.citation: Pharm Sci Technolo Today. 1999 Jul;2(7):288-298
references.pmid: 10407392
references.citation: Traffic. 2004 Mar;5(3):117-28
references.pmid: 15086788
references.citation: Int J Urol. 2013 Jun;20(6):552-62
references.pmid: 23336527